Edwards Lifesciences Corporation: goodwill carrying amount
Goodwill carrying amount for Edwards Lifesciences Corporation. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Edwards Lifesciences Corporation financial histories
What this measure means
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
Exact concept: us-gaap:Goodwill. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2008-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 1,768,600,000 | USD | 2026-02-25 | 10-K · 0001099800-26-000009 |
| At date | 2024-12-31 | 1,776,700,000 | USD | 2026-02-25 | 10-K · 0001099800-26-000009 |
| At date | 2023-12-31 | 1,145,100,000 | USD | 2026-02-25 | 10-K · 0001099800-26-000009 |
| At date | 2022-12-31 | 1,064,800,000 | USD | 2025-02-28 | 10-K · 0001099800-25-000005 |
| At date | 2021-12-31 | 1,167,900,000 | USD | 2024-02-12 | 10-K · 0001099800-24-000004 |
| At date | 2020-12-31 | 1,173,200,000 | USD | 2023-02-13 | 10-K · 0001099800-23-000005 |
| At date | 2019-12-31 | 1,167,700,000 | USD | 2022-02-14 | 10-K · 0001099800-22-000005 |
| At date | 2018-12-31 | 1,112,200,000 | USD | 2021-02-12 | 10-K · 0001099800-21-000007 |
| At date | 2017-12-31 | 1,126,500,000 | USD | 2020-02-14 | 10-K · 0001099800-20-000005 |
| At date | 2016-12-31 | 626,100,000 | USD | 2019-02-15 | 10-K · 0001099800-19-000004 |
| At date | 2015-12-31 | 628,300,000 | USD | 2018-02-16 | 10-K · 0001099800-18-000007 |
| At date | 2014-12-31 | 376,000,000 | USD | 2017-02-17 | 10-K · 0001099800-17-000008 |
| At date | 2013-12-31 | 385,400,000 | USD | 2016-02-19 | 10-K · 0001099800-16-000044 |
| At date | 2012-12-31 | 384,700,000 | USD | 2015-02-20 | 10-K · 0001047469-15-000998 |
| At date | 2011-12-31 | 349,800,000 | USD | 2014-02-28 | 10-K · 0001047469-14-001583 |
| At date | 2010-12-31 | 315,200,000 | USD | 2013-02-28 | 10-K · 0001047469-13-001954 |
| At date | 2009-12-31 | 315,200,000 | USD | 2011-02-28 | 10-K · 0001047469-11-001550 |
| At date | 2008-12-31 | 315,700,000 | USD | 2011-02-28 | 10-K · 0001047469-11-001550 |
Related financial histories
- Edwards Lifesciences Corporation: total assets
- Edwards Lifesciences Corporation: total liabilities
- Edwards Lifesciences Corporation: stockholders equity
- Edwards Lifesciences Corporation: cash and cash equivalents
- Edwards Lifesciences Corporation: net income or loss
- Edwards Lifesciences Corporation: operating cash flow
- Edwards Lifesciences Corporation: capital expenditure payments
- Edwards Lifesciences Corporation: contract revenue excluding tax
- Edwards Lifesciences Corporation: financing cash flow
- Edwards Lifesciences Corporation: investing cash flow
- Edwards Lifesciences Corporation: retained earnings or deficit
- Edwards Lifesciences Corporation: basic weighted-average shares
- Edwards Lifesciences Corporation: diluted weighted-average shares
- Edwards Lifesciences Corporation: basic earnings per share
- Edwards Lifesciences Corporation: diluted earnings per share
- Edwards Lifesciences Corporation: income tax expense or benefit
- Edwards Lifesciences Corporation: net property, plant and equipment
- Edwards Lifesciences Corporation: share-based compensation expense
- Edwards Lifesciences Corporation: operating income or loss
- Edwards Lifesciences Corporation: current assets
- Edwards Lifesciences Corporation: interest expense
- Edwards Lifesciences Corporation: current liabilities
- Edwards Lifesciences Corporation: current accounts payable
- Edwards Lifesciences Corporation: net finite-lived intangible assets
- Edwards Lifesciences Corporation: net current accounts receivable
- Edwards Lifesciences Corporation: common-stock repurchase payments
- Edwards Lifesciences Corporation: net inventory
- Edwards Lifesciences Corporation: gross profit
- Edwards Lifesciences Corporation: selling, general and administrative expense
- Edwards Lifesciences Corporation: research and development expense
Inspect the source
- Entity
- Edwards Lifesciences Corporation / CIK 0001099800
- Captured
- 2026-09-20T05:22:59.752Z
- SEC response SHA-256
5e8f751fbec9a0a1ff653c4d2070ea46d6cde3f7ccf35f9c1d7367a126bc76c1
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001099800.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))